Skip to main content

Glucosylsphingosine (Lyso-Gb1): An Informative Biomarker in the Clinical Monitoring of Patients with Gaucher Disease.

Publication ,  Journal Article
Gayed, MM; Jung, S-H; Huggins, E; Rodriguez-Rassi, E; DeArmey, S; Kishnani, PS; Stiles, AR
Published in: Int J Mol Sci
November 29, 2022

Historically, disease burden and treatment responses in patients with Gaucher disease (GD) was assessed by monitoring clinical data, laboratory, imaging, chitotriosidase (CHITO), and other biomarkers; however, these biomarkers lack specificity and CHITO is uninformative in patients heterozygous or homozygous for the CHIT1 c.1049_1072dup24 variant. Recently, glucosylsphingosine (lyso-Gb1), a sensitive and specific GD biomarker, has been recommended for patient monitoring. Furthermore, studies measuring lyso-Gb1 and CHITO in patients on long-term treatment with enzyme replacement therapy (ERT) and/or substrate reduction therapy (SRT) reported as group data show a reduction in both analytes, yet individualized patient data are generally unavailable. We describe seven patients on long-term treatment with longitudinal clinical data with monitoring based on current treatment guidelines. We present four patients who exhibit stable disease with normalized CHITO despite elevated lyso-Gb1. We present one patient who transitioned from ERT to SRT due to lack of a clinical response with life-threatening thrombocytopenia who responded with marked improvement in platelets, and normalized levels of both CHITO and lyso-Gb1. Finally, we present two ERT to SRT switch patients with stable disease on ERT who exhibited non-compliance on SRT, one with mirrored marked elevations of CHITO and lyso-Gb1; and another with normal CHITO and platelets, but increasing lyso-Gb1 levels and enlarged spleen. These clinical vignettes highlight the role of lyso-Gb1 as a sensitive biomarker in management of patients with GD, and its further value when CHITO is normal and thus uninformative. We highlight the personalized medicine approach needed to optimize treatment outcomes and recommendations for these patients.

Duke Scholars

Published In

Int J Mol Sci

DOI

EISSN

1422-0067

Publication Date

November 29, 2022

Volume

23

Issue

23

Location

Switzerland

Related Subject Headings

  • Psychosine
  • Humans
  • Gaucher Disease
  • Enzyme Replacement Therapy
  • Chemical Physics
  • Biomarkers
  • 3404 Medicinal and biomolecular chemistry
  • 3107 Microbiology
  • 3101 Biochemistry and cell biology
  • 0699 Other Biological Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gayed, M. M., Jung, S.-H., Huggins, E., Rodriguez-Rassi, E., DeArmey, S., Kishnani, P. S., & Stiles, A. R. (2022). Glucosylsphingosine (Lyso-Gb1): An Informative Biomarker in the Clinical Monitoring of Patients with Gaucher Disease. Int J Mol Sci, 23(23). https://doi.org/10.3390/ijms232314938
Gayed, Matthew M., Seung-Hye Jung, Erin Huggins, Eleanor Rodriguez-Rassi, Stephanie DeArmey, Priya Sunil Kishnani, and Ashlee R. Stiles. “Glucosylsphingosine (Lyso-Gb1): An Informative Biomarker in the Clinical Monitoring of Patients with Gaucher Disease.Int J Mol Sci 23, no. 23 (November 29, 2022). https://doi.org/10.3390/ijms232314938.
Gayed MM, Jung S-H, Huggins E, Rodriguez-Rassi E, DeArmey S, Kishnani PS, et al. Glucosylsphingosine (Lyso-Gb1): An Informative Biomarker in the Clinical Monitoring of Patients with Gaucher Disease. Int J Mol Sci. 2022 Nov 29;23(23).
Gayed, Matthew M., et al. “Glucosylsphingosine (Lyso-Gb1): An Informative Biomarker in the Clinical Monitoring of Patients with Gaucher Disease.Int J Mol Sci, vol. 23, no. 23, Nov. 2022. Pubmed, doi:10.3390/ijms232314938.
Gayed MM, Jung S-H, Huggins E, Rodriguez-Rassi E, DeArmey S, Kishnani PS, Stiles AR. Glucosylsphingosine (Lyso-Gb1): An Informative Biomarker in the Clinical Monitoring of Patients with Gaucher Disease. Int J Mol Sci. 2022 Nov 29;23(23).

Published In

Int J Mol Sci

DOI

EISSN

1422-0067

Publication Date

November 29, 2022

Volume

23

Issue

23

Location

Switzerland

Related Subject Headings

  • Psychosine
  • Humans
  • Gaucher Disease
  • Enzyme Replacement Therapy
  • Chemical Physics
  • Biomarkers
  • 3404 Medicinal and biomolecular chemistry
  • 3107 Microbiology
  • 3101 Biochemistry and cell biology
  • 0699 Other Biological Sciences